BMS CCR2 22 structure
|
Common Name | BMS CCR2 22 | ||
---|---|---|---|---|
CAS Number | 445479-97-0 | Molecular Weight | 593.66100 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C28H34F3N5O4S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of BMS CCR2 22BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM)[1][2]. |
Name | N-[2-[[(1R,2S)-2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide |
---|---|
Synonym | More Synonyms |
Description | BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM)[1][2]. |
---|---|
Related Catalog | |
Target |
CCR2:5.1 nM (IC50) |
In Vitro | BMS CCR2 22 (Compound 22) has binding affinity for wild-type and E291A mutants with IC50 values of 7.5 nM and 3.7 nM, respectively[1].BMS CCR2 22 prevents both the binding and the internalization of fluorescently labeled hMCP-1_AF647 internalization in human monocytes. BMS CCR2 22 inhibits the internalization of hMCP1_AF647 with an IC50 value of approximately 2 nM[2]. The addition of BMS CCR2 22 (0.1-10 μM; 24 h), cenicriviroc (CVC) or a combination of both BMS CCR2 22 and MVC to human aortic endothelial cells (HAoECs) prior to MCP-1 stimulation do not alter E-selectin, ICAM-1, or CD99 cell surface expression. Incubation of HAoECs with BMS CCR2 22 before MCP-1 significantly increases VCAM-1 and PECAM1 cell surface levels (from 72.8 to 160% and from 97.2 and 127%, respectively)[3]. |
References |
Molecular Formula | C28H34F3N5O4S |
---|---|
Molecular Weight | 593.66100 |
Exact Mass | 593.22800 |
PSA | 153.73000 |
LogP | 6.18100 |
Carboxy-PTIO,potassium salt |